Dyne Therapeutics Submits BLA for z-rostudirsen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Dyne Therapeutics announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for zeleciment rostudirsen, z-rostudirsen, 20 mg/kg Q4W for the treatment of individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. Dyne has requested Priority Review for the BLA, which, if granted, would shorten the review process from 10 months to 6 months following the FDA's 60-day filing review period. Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming the FDA grants Priority Review and approval is received on the anticipated timeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 18.560
Low
17.00
Averages
39.33
High
60.00
Current: 18.560
Low
17.00
Averages
39.33
High
60.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FCPM III Services B.V. Reduces Stake in Dyne Therapeutics
- Share Reduction Transaction: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, with an estimated transaction value of $14.11 million, indicating the fund's sustained confidence as Dyne now represents 11.8% of its holdings.
- Market Performance: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress: Dyne is advancing its Biologics License Application for z-rostudirsen, a treatment for Duchenne muscular dystrophy, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, which could present significant market opportunities for the company.
- Clinical Trial Launch: Dyne recently initiated the FORZETTO study, aiming to enroll approximately 90 patients over 72 weeks, designed to demonstrate meaningful functional improvements, which will lay the groundwork for future commercialization efforts.
See More
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Dyne Therapeutics Submits BLA for DMD Treatment Z-rostudirsen
- BLA Submission: Dyne Therapeutics has submitted a Biologics License Application (BLA) to the FDA for Z-rostudirsen, targeting Duchenne muscular dystrophy (DMD) patients eligible for exon 51 skipping, marking a significant advancement in the rare disease sector.
- Clinical Trial Success: In the registrational expansion cohort of the DELIVER trial, patients treated with Z-rostudirsen demonstrated a statistically significant increase in dystrophin production and functional improvements across multiple clinical endpoints, validating the therapy's efficacy and safety profile.
- Market Potential: According to Grand View Research, the DMD drug market is projected to grow from $3.47 billion in 2023 to $9.91 billion by 2030, with a CAGR of 16.8%, providing a promising growth opportunity for Dyne's future.
- FDA Priority Review: Dyne has requested a priority review from the FDA for Z-rostudirsen, with plans to launch in the U.S. market in Q1 2027 if approved, which would significantly enhance the company's market position in DMD treatment.
See More
Dyne Therapeutics Submits BLA for Accelerated Approval of z-rostudirsen
- Clinical Trial Success: In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a statistically significant increase in dystrophin production, with functional improvements observed across multiple clinical endpoints, indicating its potential therapeutic efficacy.
- Accelerated Review Application: Dyne Therapeutics has submitted a Biologics License Application (BLA) to the FDA requesting Priority Review, which, if granted, would shorten the review process from 10 months to 6 months, with a potential U.S. launch of z-rostudirsen anticipated in Q1 2027.
- Multiple Treatment Candidates: In addition to z-rostudirsen, Dyne is advancing four other development candidates targeting different exons (DYNE-253, DYNE-245, DYNE-244, and DYNE-255), showcasing the company's extensive pipeline in the Duchenne muscular dystrophy space.
- Strong Market Demand: Despite existing therapies, there remains a significant unmet need among DMD patients, and the development of z-rostudirsen aims to provide improved efficacy and safety while reducing treatment burden, addressing the urgent demand for new therapeutic options.
See More
Dyne Therapeutics Grants Inducement Equity Awards to New Employees
- Equity Award Program: Dyne Therapeutics has granted inducement equity awards to 17 new employees, comprising 296,500 non-statutory stock options and 94,100 restricted stock units, aimed at attracting top talent and strengthening the team.
- Option Details: The stock options have an exercise price equal to the closing price on May 20, 2026, with a ten-year term and a four-year vesting schedule, where 25% vests in the first year and the remainder vests quarterly, ensuring employee retention.
- Restricted Stock Units: The restricted stock units will vest in equal annual installments over four years, designed to incentivize employees to grow with the company and enhance their loyalty and engagement.
- Company Mission: Dyne Therapeutics focuses on delivering functional improvements for patients with genetically driven neuromuscular diseases, advancing clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, reflecting the company's commitment to improving patient quality of life.
See More
Dyne Therapeutics Initiates Late-Stage DMD Trial for z-rostudirsen
- Global Trial Launch: Dyne Therapeutics has initiated a global late-stage confirmatory trial for z-rostudirsen targeting Duchenne muscular dystrophy (DMD), planning to enroll approximately 90 ambulatory boys and young men aged 4 to 18, which is crucial for converting accelerated approval into full traditional approval, highlighting the company's strategic positioning in DMD treatment.
- FDA Alignment on Trial Design: The trial has been aligned with the U.S. Food and Drug Administration (FDA) and features a randomized, placebo-controlled, double-blind design, with participants receiving 20 mg/kg of z-rostudirsen or placebo every four weeks for 72 weeks, where the primary endpoint is the change in rise-from-floor velocity at Week 73, ensuring the clinical validity and reliability of results.
- Positive Market Reaction: Following the trial announcement, Dyne Therapeutics' shares surged 8% on Wednesday, reflecting investor optimism regarding the company's prospects in the DMD space, with a 40% stock price increase over the past 12 months, indicating strong market confidence in its growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, 14 out of 16 analysts covering DYN rate it as Buy or higher, with a 12-month average price target of $38.19, suggesting a potential upside of about 140% from its last close, demonstrating positive expectations for its future performance.
See More
FCPM III Services B.V. Reduces Stake in Dyne Therapeutics
- Share Reduction Transaction: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, with an estimated transaction value of $14.11 million, indicating the fund's sustained confidence as Dyne now represents 11.8% of its holdings.
- Market Performance: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress: Dyne is advancing its Biologics License Application for z-rostudirsen, a treatment for Duchenne muscular dystrophy, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, which could present significant market opportunities for the company.
- Clinical Trial Launch: Dyne recently initiated the FORZETTO study, aiming to enroll approximately 90 patients over 72 weeks, designed to demonstrate meaningful functional improvements, which will lay the groundwork for future commercialization efforts.
See More
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Dyne Therapeutics Submits BLA for DMD Treatment Z-rostudirsen
- BLA Submission: Dyne Therapeutics has submitted a Biologics License Application (BLA) to the FDA for Z-rostudirsen, targeting Duchenne muscular dystrophy (DMD) patients eligible for exon 51 skipping, marking a significant advancement in the rare disease sector.
- Clinical Trial Success: In the registrational expansion cohort of the DELIVER trial, patients treated with Z-rostudirsen demonstrated a statistically significant increase in dystrophin production and functional improvements across multiple clinical endpoints, validating the therapy's efficacy and safety profile.
- Market Potential: According to Grand View Research, the DMD drug market is projected to grow from $3.47 billion in 2023 to $9.91 billion by 2030, with a CAGR of 16.8%, providing a promising growth opportunity for Dyne's future.
- FDA Priority Review: Dyne has requested a priority review from the FDA for Z-rostudirsen, with plans to launch in the U.S. market in Q1 2027 if approved, which would significantly enhance the company's market position in DMD treatment.
See More
Dyne Therapeutics Submits BLA for Accelerated Approval of z-rostudirsen
- Clinical Trial Success: In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a statistically significant increase in dystrophin production, with functional improvements observed across multiple clinical endpoints, indicating its potential therapeutic efficacy.
- Accelerated Review Application: Dyne Therapeutics has submitted a Biologics License Application (BLA) to the FDA requesting Priority Review, which, if granted, would shorten the review process from 10 months to 6 months, with a potential U.S. launch of z-rostudirsen anticipated in Q1 2027.
- Multiple Treatment Candidates: In addition to z-rostudirsen, Dyne is advancing four other development candidates targeting different exons (DYNE-253, DYNE-245, DYNE-244, and DYNE-255), showcasing the company's extensive pipeline in the Duchenne muscular dystrophy space.
- Strong Market Demand: Despite existing therapies, there remains a significant unmet need among DMD patients, and the development of z-rostudirsen aims to provide improved efficacy and safety while reducing treatment burden, addressing the urgent demand for new therapeutic options.
See More
Dyne Therapeutics Grants Inducement Equity Awards to New Employees
- Equity Award Program: Dyne Therapeutics has granted inducement equity awards to 17 new employees, comprising 296,500 non-statutory stock options and 94,100 restricted stock units, aimed at attracting top talent and strengthening the team.
- Option Details: The stock options have an exercise price equal to the closing price on May 20, 2026, with a ten-year term and a four-year vesting schedule, where 25% vests in the first year and the remainder vests quarterly, ensuring employee retention.
- Restricted Stock Units: The restricted stock units will vest in equal annual installments over four years, designed to incentivize employees to grow with the company and enhance their loyalty and engagement.
- Company Mission: Dyne Therapeutics focuses on delivering functional improvements for patients with genetically driven neuromuscular diseases, advancing clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, reflecting the company's commitment to improving patient quality of life.
See More
Dyne Therapeutics Initiates Late-Stage DMD Trial for z-rostudirsen
- Global Trial Launch: Dyne Therapeutics has initiated a global late-stage confirmatory trial for z-rostudirsen targeting Duchenne muscular dystrophy (DMD), planning to enroll approximately 90 ambulatory boys and young men aged 4 to 18, which is crucial for converting accelerated approval into full traditional approval, highlighting the company's strategic positioning in DMD treatment.
- FDA Alignment on Trial Design: The trial has been aligned with the U.S. Food and Drug Administration (FDA) and features a randomized, placebo-controlled, double-blind design, with participants receiving 20 mg/kg of z-rostudirsen or placebo every four weeks for 72 weeks, where the primary endpoint is the change in rise-from-floor velocity at Week 73, ensuring the clinical validity and reliability of results.
- Positive Market Reaction: Following the trial announcement, Dyne Therapeutics' shares surged 8% on Wednesday, reflecting investor optimism regarding the company's prospects in the DMD space, with a 40% stock price increase over the past 12 months, indicating strong market confidence in its growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, 14 out of 16 analysts covering DYN rate it as Buy or higher, with a 12-month average price target of $38.19, suggesting a potential upside of about 140% from its last close, demonstrating positive expectations for its future performance.
See More
